NCT04513925 (SKYSCRAPER-03) is a Phase 3 clinical trial of Atezolizumab in Non-small Cell Lung Cancer (NSCLC), sponsored by Hoffmann-La Roche.

Who is sponsoring NCT04513925?

NCT04513925 is sponsored by Hoffmann-La Roche.

What drugs are being tested in NCT04513925?

Interventions in NCT04513925: Atezolizumab, Tiragolumab, Durvalumab.

What condition does NCT04513925 study?

NCT04513925 studies Non-small Cell Lung Cancer (NSCLC).

Is NCT04513925 still recruiting?

NCT04513925 is currently completed. Last updated 8 September 2025.

Last reviewed 2025-09-08 · How we verify

NCT04513925: SKYSCRAPER-03

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Completed Phase 3 Last updated 8 September 2025

What this trial tests

Phase 3 trial testing Atezolizumab in Non-small Cell Lung Cancer (NSCLC) in 829 participants. Completed in 31 July 2025.

Timeline

24 August 2020

Primary endpoint
27 May 2025

31 July 2025

Quick facts

Lead sponsor	Hoffmann-La Roche
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	829
Start date	24 August 2020
Primary completion	27 May 2025
Estimated completion	31 July 2025
Sites	177 locations across Hong Kong, Italy, Japan, Taiwan, Poland, South Korea, New Zealand, Netherlands

Drugs / interventions tested

Atezolizumab (atezolizumab) — full drug profile →
Tiragolumab (tiragolumab) — full drug profile →
Durvalumab — full drug profile →

Conditions studied

Non-small Cell Lung Cancer (NSCLC) — all drugs for Non-small Cell Lung Cancer (NSCLC) →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer (NSCLC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Mamdani H, Matosevic S, Khalid AB, Durm G, et al · · 2022 · cited 253× · PMID 35222404 · DOI 10.3389/fimmu.2022.823618
Antibodies to watch in 2021.
Kaplon H, Reichert JM. · · 2021 · cited 215× · PMID 33459118 · DOI 10.1080/19420862.2020.1860476
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. · · 2021 · cited 166× · PMID 34367161 · DOI 10.3389/fimmu.2021.699895
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.
Chu X, Tian W, Wang Z, Zhang J, et al · · 2023 · cited 147× · PMID 37291608 · DOI 10.1186/s12943-023-01800-3
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials.
Niu Z, Jin R, Zhang Y, Li H. · · 2022 · cited 127× · PMID 36198685 · DOI 10.1038/s41392-022-01200-x
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.
Lee JB, Kim HR, Ha SJ. · · 2022 · cited 124× · PMID 35291660 · DOI 10.4110/in.2022.22.e2
Anti-TIGIT therapies for solid tumors: a systematic review.
Rousseau A, Parisi C, Barlesi F. · · 2023 · cited 111× · PMID 36933320 · DOI 10.1016/j.esmoop.2023.101184
TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.
Yeo J, Ko M, Lee DH, Park Y, et al · · 2021 · cited 98× · PMID 33670993 · DOI 10.3390/ph14030200

Verify or expand the search:

Other trials of Atezolizumab

Trials testing the same drug.

NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec · Phase 3 · not yet recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting

Other recruiting trials for Non-small Cell Lung Cancer (NSCLC)

Currently open trials in the same condition.

NCT07361497 — A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresec · Phase 3 · recruiting
NCT07288177 — Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer · Phase 2 · recruiting
NCT07223047 — A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agent · Phase 1, PHASE2 · recruiting
NCT07291037 — Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic N · Phase 3 · recruiting
NCT07140016 — A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) · Phase 1 · recruiting

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04513925 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 8 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04513925.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing